Cargando…
Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
BACKGROUND: Lower gastrointestinal (GI) tract involvement can affect up to 50% of systemic sclerosis (SSc) patients, and may result in malabsorption, pseudo-obstruction, hospitalization, and death. We report our experience with linaclotide, a selective agonist of guanylate cyclase C (GC-C), for SSc...
Autores principales: | Dein, Eric J., Wigley, Fredrick M., McMahan, Zsuzsanna H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051106/ https://www.ncbi.nlm.nih.gov/pubmed/33858329 http://dx.doi.org/10.1186/s12876-021-01738-0 |
Ejemplares similares
-
Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis
por: Wallwork, Rachel, et al.
Publicado: (2022) -
Gastrointestinal Involvement in Systemic Sclerosis: An Update
por: Miller, John B., et al.
Publicado: (2018) -
Micronutrient Deficiencies in Systemic Sclerosis: A Scoping Review
por: Nguyen, Audrey D, et al.
Publicado: (2022) -
Biomarkers of pulmonary hypertension in patients with scleroderma: a case–control study
por: McMahan, Zsuzsanna, et al.
Publicado: (2015) -
Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)